Biocon, Bristol-Myers sign drug deal
- Navjot Sidhu: Quit RS because I was told to stay away from Punjab
- Chinkara poaching case: Salman Khan acquitted by Rajasthan High Court
- SC issues notice to Vijay Mallya on bank plea seeking contempt proceedings
- Journalists' visa issue: Chinese media warns India of repercussions
- Parliament LIVE: Speaker Mahajan advises Mann not to attend proceedings till decision arrived at
Biocon Ltd, India's top-listed biotechnology company, said it signed an agreement with Bristol-Myers Squibb Co under which the U.S. drugmaker will have the option to get the worldwide licence to its oral insulin drug programme.
Bristol Myers can choose to assume full responsibility for the development of the drug IN-105, if its mid-stage trial is successful.
Biocon, which has been looking to partner the drug for nearly two years, said it would receive a licence fee as well as milestone payments and royalties based on commercial sales of the drug outside India.
It will retain the rights to IN-105 in India. Financial terms of the deal were not available.
Currently, there are no insulin tablets available and patients with diabetes who need insulin – a naturally occurring protein that controls blood sugar – must inject it.
Earlier this year, Pfizer scrapped a deal to sell injectable insulin products made by Biocon.
Biocon shares, which rose more than 4 percent in the previous session, were down 0.4 percent on Friday, while the broader market was up 0.3 percent.
Company INFO More on Biocon
Stocks More on Biocon
Biocon inks pact with Bristol-Myers for insulin drug candidate
New Delhi,(PTI): Biotechnology major Biocon today said it has entered into an agreement with Bristol-Myers Squibb for it's oral insulin new drug candidate IN- 105.
Under the terms of the option agreement, Bristol- Myers Squibb will have the right to exercise an option to obtain an exclusive worldwide licence to the programme.
It will, however, conduct the clinical trials according to a pre-agreed development programme up to the completion of Phase II, as per the agreement, Biocon said.
- BJP was not dependent on Dalits to win Gujarat. But the apathy may cost in other states
- Jayalalithaa and Mamata defend Mayawati, recast politics on gender lines
- The Worship of False Gods
- As Trump’s support cuts across traditional lines, Hillary Clinton has a tough task
- SH Raza He was the last of Progressive Artists’ Group titans. Only the Bindu remains
- The recent violence against Dalits in Gujarat is a fallout of the Sangh Parivar’s diktats on food